slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 75,871-75,900
Pages 3,225
Rows per page 30
Component
75,871-75,900 of 96,741
152
The slide uses direct quotes from industry experts to build a case against TransMedics' business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
153
The slide uses a Q&A format to highlight potential misuse of system access.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
154
Includes a direct quote from an unnamed source regarding the company's technicians.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a 'fraud-exposure' framework to contrast alleged real-world usage with official FDA labeling.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses a combination of qualitative expert interview summaries and quantitative data from the company's own investor presentation to frame the company's clinical claims as a 'ruse'.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
157
The slide uses a testimonial to undermine the corporate narrative of 'Game Changer' technology, suggesting it is instead a tool for labor convenience.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
158
The slide uses a testimonial/interview format to challenge the necessity of the OCS device for local transplants.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
159
The slide uses Q&A transcripts to undermine a business model premise.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
160
The slide uses direct quotes from transplant directors to challenge the value proposition of TransMedics' NOP service.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a Q&A format to substantiate the claim of reckless off-label usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
162
The slide uses a Q&A format to present expert testimony regarding potential misuse of medical devices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a primary headline followed by a detailed supporting quote, highlighting the ethical and financial concerns regarding off-label use of perfusion technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
165
The slide uses a Q&A format to present a negative testimonial/critique of the company's sales tactics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
167
Uses direct quotes from surgeons at Utah and UCSD to support the thesis of off-label, convenience-driven usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
168
The slide uses direct quotes to highlight a discrepancy between the purported clinical value of the device and the actual operational use case.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses direct quotes from anonymous experts to build a case of 'expensive abuse' of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a Q&A transcript format to build a case against the clinical justification of the product's usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
171
The slide uses expert quotes to frame 'back to base' usage as a potentially harmful, off-label practice driven by convenience rather than clinical necessity.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a Q&A format to highlight a specific industry pain point regarding the misuse of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
173
The slide highlights a specific operational failure (delayed pump usage) causing a 10% loss rate in the region.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
174
The slide contrasts the author's claims of widespread off-label use with the official FDA 'Indications for Use' text.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a 'villain_critique' approach by quoting an ex-employee to expose what the author considers to be fraudulent medical claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
176
The slide uses a table from a JAMA Surgery paper to highlight the mean donor age in the trial (45.9 years) as evidence of selection bias.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
177
Includes a Q&A transcript excerpt highlighting the risks of off-label use beyond the 30-minute window.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
179
The slide uses a Q&A transcript format to highlight the discrepancy between regulatory guidelines and real-world surgical behavior.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
181
The slide uses a combination of narrative summary and verbatim Q&A transcripts to highlight discrepancies between trial conditions and real-world usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
183
The slide uses direct quotes from a transplant surgeon to expose potential malpractice or dangerous usage patterns.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
184
The slide uses a Q&A transcript format to frame the company's business model as 'quackery' and reliant on 'marginal' organs.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
185
The slide uses a 'villain' narrative style to frame the company's business practices as risky or non-compliant.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
186
The slide uses expert testimony to challenge the value proposition of the TransMedics technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit